Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA OK for CMS' Atlas-based Autosegmentation

This article was originally published in Clinica

Executive Summary

The US FDA has granted 510(k) clearance for CMS' Atlas-based Autosegmentation (ABAS) software, which produces estimates of anatomy boundary contours to create a radiotherapy treatment plan. The St Louis, Missouri-based company, a subsidiary of Stockholm, Sweden-based Elekta, filed the product in April. The software helps clinicians save time, CMS says, as contouring is usually a time-consuming process. ABAS is also compatible with any radiation treatment planning system that can read standard DICOM RT structure set files, distinguishing it from competing products, the firm added. It has structure-specific algorithms for head and neck and prostate cancer treatments, as well as a general algorithm for other sites.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041668

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel